FindTrial
Sign In

Cabotegravir Injectable Suspension

DRUG4 trials

Sponsors

ViiV Healthcare, University of California, San Francisco, University of Zurich

Conditions

HIVHIV InfectionsHuman Immunodeficiency Virus Type 1 (HIV-1)

Phase 3

Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults
Active, not recruitingNCT03299049
ViiV HealthcareHIV Infections
Start: 2017-10-27End: 2029-12-31Updated: 2025-08-22
A Sub-study of Cabotegravir (CAB) and Rilpivirine (RPV) in Human Immunodeficiency Viruses (HIV)-Infected Participants
CompletedNCT05896761
ViiV HealthcareHuman Immunodeficiency Virus Type 1 (HIV-1)
Start: 2021-10-28End: 2022-08-23Updated: 2023-09-18

Phase 4

SEARCH CAB LA Dynamic Choice HIV Prevention Study Extension
CompletedNCT05549726
University of California, San FranciscoHIV
Start: 2023-01-02End: 2025-01-30Updated: 2026-08-26

Unknown Phase

Cabotegravir Plus Rilpivirine Long-acting Regimen in the Swiss HIV Cohort Study:Uptake, Outcome, and Risk Factors for Treatment Failures
RecruitingNCT06405464
University of ZurichHIV Infections
Start: 2022-03-01End: 2026-06-30Target: 600Updated: 2024-05-08

Related Papers

Dynamic choice HIV prevention with cabotegravir long-acting injectable in rural Uganda and Kenya: a randomised trial extension.
2024-10-0920 citations
Efficacy, Safety, and Pharmacokinetics by Body Mass Index Category in Phase 3/3b Long-Acting Cabotegravir Plus Rilpivirine Trials.
2024-07-0111 citations
Long-acting cabotegravir pharmacokinetics with and without oral lead-in for HIV PrEP
Antimicrobial Agents and Chemotherapy2024-05-067 citations
Asian participants' experience in phase 3/3b studies of long‐acting cabotegravir and rilpivirine: Efficacy, safety, pharmacokinetic, and virological outcomes through week 96
HIV Medicine2023-12-261 citations
Cabotegravir and Rilpivirine Long-Acting Antiretroviral Therapy Administered Every 2 Months is Cost-Effective for the Treatment of HIV-1 in Spain.
2023-07-1410 citations
Indirect comparison of 48-week efficacy and safety of long-acting cabotegravir and rilpivirine maintenance every 8 weeks with daily oral standard of care antiretroviral therapy in participants with virologically suppressed HIV-1-infection.
2022-05-042 citations
Safety, Tolerability, Pharmacokinetics, and Acceptability of Oral and Long-Acting Cabotegravir in HIV-Negative Chinese Men.
2022-02-079 citations
875. Indirect Treatment Comparison of 48-Week Efficacy and Safety of Cabotegravir + Rilpivirine Long-Acting Every 2 Months to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Suppressed HIV-1 Infected Participants
Open Forum Infectious Diseases2021-11-01
Long-acting cabotegravir and rilpivirine for HIV-1 suppression: switch to 2-monthly dosing after 5 years of daily oral therapy
AIDS2021-10-1334 citations
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.
2021-10-11103 citations
Week 96 extension results of a Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment
AIDS2021-07-1392 citations
Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M).
2021-05-3156 citations
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.
2020-12-09259 citations
Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials
JAIDS Journal of Acquired Immune Deficiency Syndromes2020-08-21135 citations